富碘中药治疗Graves病专家共识

2021-06-20 中国中西医结合学会 中国中西医结合杂志. 2021,41(06)

Graves病(Graves’disease,GD)是一种以甲状腺激素分泌异常增多为主要特征的器官特异性自身免疫性疾病,约占所有甲状腺功能亢进症(简称甲亢)的85%。本病属中医学"瘿病""

中文标题:

富碘中药治疗Graves病专家共识

发布机构:

中国中西医结合学会

发布日期:

2021-06-20

简要介绍:

Graves病(Graves’disease,GD)是一种以甲状腺激素分泌异常增多为主要特征的器官特异性自身免疫性疾病,约占所有甲状腺功能亢进症(简称甲亢)的85%。本病属中医学"瘿病""瘿气"等范畴。海藻、昆布、海带是碘含量丰富的中药,东汉时期《神农本草经》最早记载海藻"味苦,寒,无毒。治瘿瘤气……";《千金翼方》《外台秘要》均记载用海藻治瘿;海藻玉壶汤、活血消瘿汤、十全流气汤、四海舒郁丸,均是以富碘中药为君药的治瘿方剂。古代治瘿方剂用药规律研究表明富碘中药应用频次较高。 

相关资料下载:
[AttachmentFileName(sort=1, fileName=富碘中药治疗Graves病专家共识_中国中西医结合学会内分泌学专业委员会.pdf)] GetToolGuiderByIdResponse(projectId=1, id=257ee1c002128975, title=富碘中药治疗Graves病专家共识 , enTitle=, guiderFrom=中国中西医结合杂志. 2021,41(06), authorId=0, author=, summary=Graves病(Graves’disease,GD)是一种以甲状腺激素分泌异常增多为主要特征的器官特异性自身免疫性疾病,约占所有甲状腺功能亢进症(简称甲亢)的85%。本病属中医学"瘿病"", cover=https://img.medsci.cn/2021715/1626284077731_2020535.jpg, journalId=0, articlesId=null, associationId=759, associationName=中国中西医结合学会, associationIntro=中国中西医结合学会是中西医结合医学科学技术工作者组成的学术性群众团体,是依法成立的社团法人,是中国科学技术协会的团体会员。, copyright=0, guiderPublishedTime=Sun Jun 20 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #666666;">Graves病(Graves&rsquo;disease,GD)是一种以甲状腺激素分泌异常增多为主要特征的器官特异性自身免疫性疾病,约占所有甲状腺功能亢进症(简称甲亢)的85%。本病属中医学"瘿病""瘿气"等范畴。海藻、昆布、海带是碘含量丰富的中药,东汉时期《神农本草经》最早记载海藻"味苦,寒,无毒。治瘿瘤气&hellip;&hellip;"</span><span style="color: #666666;">;《千金翼方》</span><span style="color: #666666;">《外台秘要》</span><span style="color: #666666;">均记载用海藻治瘿;海藻玉壶汤、活血消瘿汤、十全流气汤、四海舒郁丸,均是以富碘中药为君药的治瘿方剂</span><span style="color: #666666;">。古代治瘿方剂用药规律研究表明富碘中药应用频次较高</span><span style="color: #666666;">。&nbsp;</span></p>, tagList=[TagDto(tagId=12349, tagName=Graves病)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=37, categoryName=中医科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=12349, guiderKeyword=Graves病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=9098, appHits=73, showAppHits=0, pcHits=530, showPcHits=9022, likes=0, shares=5, comments=5, approvalStatus=1, publishedTime=Thu Jul 15 01:51:49 CST 2021, publishedTimeString=2021-06-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Thu Jul 15 01:34:47 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 21:11:11 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=富碘中药治疗Graves病专家共识_中国中西医结合学会内分泌学专业委员会.pdf)])
富碘中药治疗Graves病专家共识_中国中西医结合学会内分泌学专业委员会.pdf
下载请点击:
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1082575, encodeId=723610825e5ad, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a075617739, createdName=杨云姣, createdTime=Tue Dec 21 14:43:10 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080638, encodeId=34021080638e9, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:52:38 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001683, encodeId=2a901001683d6, content=谢谢 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79b75554426, createdName=cyjen, createdTime=Thu Jul 22 14:07:58 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000223, encodeId=702210002235d, content=谢谢 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f221859736, createdName=ms2658711348342440, createdTime=Fri Jul 16 22:09:35 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999741, encodeId=abc3999e411e, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLiaB0iaEcgjgpwAktr7UdLtlr3GctcIT0lod9ku49LdicibcibKUkBfwqJEoeWNLeTsiamoxeiccialvapXw/132, createdBy=21752501008, createdName=李洪520, createdTime=Thu Jul 15 13:59:08 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
    2021-12-21 杨云姣

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1082575, encodeId=723610825e5ad, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a075617739, createdName=杨云姣, createdTime=Tue Dec 21 14:43:10 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080638, encodeId=34021080638e9, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:52:38 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001683, encodeId=2a901001683d6, content=谢谢 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79b75554426, createdName=cyjen, createdTime=Thu Jul 22 14:07:58 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000223, encodeId=702210002235d, content=谢谢 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f221859736, createdName=ms2658711348342440, createdTime=Fri Jul 16 22:09:35 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999741, encodeId=abc3999e411e, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLiaB0iaEcgjgpwAktr7UdLtlr3GctcIT0lod9ku49LdicibcibKUkBfwqJEoeWNLeTsiamoxeiccialvapXw/132, createdBy=21752501008, createdName=李洪520, createdTime=Thu Jul 15 13:59:08 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
    2021-12-16 龙珠

    学习好资料

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1082575, encodeId=723610825e5ad, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a075617739, createdName=杨云姣, createdTime=Tue Dec 21 14:43:10 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080638, encodeId=34021080638e9, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:52:38 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001683, encodeId=2a901001683d6, content=谢谢 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79b75554426, createdName=cyjen, createdTime=Thu Jul 22 14:07:58 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000223, encodeId=702210002235d, content=谢谢 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f221859736, createdName=ms2658711348342440, createdTime=Fri Jul 16 22:09:35 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999741, encodeId=abc3999e411e, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLiaB0iaEcgjgpwAktr7UdLtlr3GctcIT0lod9ku49LdicibcibKUkBfwqJEoeWNLeTsiamoxeiccialvapXw/132, createdBy=21752501008, createdName=李洪520, createdTime=Thu Jul 15 13:59:08 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
    2021-07-22 cyjen

    谢谢 学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1082575, encodeId=723610825e5ad, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a075617739, createdName=杨云姣, createdTime=Tue Dec 21 14:43:10 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080638, encodeId=34021080638e9, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:52:38 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001683, encodeId=2a901001683d6, content=谢谢 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79b75554426, createdName=cyjen, createdTime=Thu Jul 22 14:07:58 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000223, encodeId=702210002235d, content=谢谢 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f221859736, createdName=ms2658711348342440, createdTime=Fri Jul 16 22:09:35 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999741, encodeId=abc3999e411e, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLiaB0iaEcgjgpwAktr7UdLtlr3GctcIT0lod9ku49LdicibcibKUkBfwqJEoeWNLeTsiamoxeiccialvapXw/132, createdBy=21752501008, createdName=李洪520, createdTime=Thu Jul 15 13:59:08 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
    2021-07-16 ms2658711348342440

    谢谢 学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1082575, encodeId=723610825e5ad, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a075617739, createdName=杨云姣, createdTime=Tue Dec 21 14:43:10 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080638, encodeId=34021080638e9, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:52:38 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001683, encodeId=2a901001683d6, content=谢谢 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79b75554426, createdName=cyjen, createdTime=Thu Jul 22 14:07:58 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000223, encodeId=702210002235d, content=谢谢 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f221859736, createdName=ms2658711348342440, createdTime=Fri Jul 16 22:09:35 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999741, encodeId=abc3999e411e, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLiaB0iaEcgjgpwAktr7UdLtlr3GctcIT0lod9ku49LdicibcibKUkBfwqJEoeWNLeTsiamoxeiccialvapXw/132, createdBy=21752501008, createdName=李洪520, createdTime=Thu Jul 15 13:59:08 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
    2021-07-15 李洪520

    0

拓展阅读

2016 JTA指南:儿童时期发病的Graves病的管理

日本甲状腺协会(JTA,Japan Thyroid Association) · 2017-04-22